Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. This breakthrough marks the first of its kind in China and represents a significant milestone… Read More
A Spanish study has shown that PRP, a mixture of two proenzymes, trypsinogen and chymotrypsinogen, suppresses the TGF-β pathway and the tumour microenvironment in pancreatic cancer. The study was co-led by Belén Toledo Cutillas, at the laboratory of Professor Macarena Perán, University of Jaén, Granada, Spain. Read More
Astellas Pharma and MIMETAS, which specialises in human disease modelling, have entered a strategic partnership to develop treatments for cancer. The companies will use MIMETAS’ tumour models to support the next generation of immuno-oncological therapies. “We are excited to make this next step in… Read More
iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, has been awarded the innovative medicine designation, the Innovation Passport, for roginolisib, for the treatment of metastatic uveal melanoma by the Medicines & Healthcare products Regulatory Agency (MHRA). Roginolisib is a first-in-class, non-ATP-competitive,… Read More
Merck has bought the exclusive worldwide rights to develop, manufacture and commercialise anti PD-L1 antibody Bavencio (avelumab) from Pfizer. Merck will take full control of the global commercialisation of Bavencio through its affiliate Ares Trading. The transaction has also ended a long-term collaboration between Merck and Pfizer. The current profit… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of developments in the treatment of solid tumours… Read More
Macomics and Ono Pharmaceutical have entered a worldwide drug discovery collaboration agreement to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Under the terms of the agreement, Macomics will identify and characterise antibody candidates against the novel target of interest… Read More
News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer. This week we have seen a number of developments in the treatment of solid tumours hitting the headlines. Pennsylvania researchers may have found a way to boost CAR-T therapy in these tumours, previously only successful in… Read More
This latest ebook sponsored by Sino Biological features insight on how the global drug discovery and development sector is making breakthroughs in cancer research. Download this exclusive eBook to learn more about: The global developments tackling the burden of cancer … Read More
This latest eBook sponsored by Sino Biological features insight on how the global drug discovery and development sector is making breakthroughs in cancer research. Download this exclusive eBook to learn more about: The global developments tackling the burden of cancer Advances and challenges… Read More
iOnctura, a clinical stage biotechnology company developing cancer therapies, has published non-clinical research on roginolisib in the AACR journal Cancer Research Communications. Roginolisib is a first-in-class, non-ATP-competitive, allosteric modulator of PI3Kd which prevents tumour proliferation and breaks immune tolerance in patients with solid and haematological… Read More
Purple Biotech has revealed positive new results from exploratory analyses conducted as part of a Phase I dose escalation study into CM24 plus nivolumab for advanced cancer. The study enrolled 14 patients with advanced cancers including 11 patients with pancreatic adenocarcinoma (PDAC), two patients with colorectal… Read More
A new approach that delivers a ‘one-two punch’ to help T cells attack solid tumours is the focus of a preclinical study by researchers from the Perelman School of Medicine at the University of Pennsylvania. The findings showed that targeting two regulators that control gene functions… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the news this week, we have covered a number of early-stage studies that could… Read More
Diana Spencer explores the different ways the drug discovery sector is tackling colorectal cancer. Colorectal cancer is preventable with screening and often treatable when caught early, yet due to late diagnosis and chemotherapy resistance, it remains the second deadliest cancer in the United States. Held in the US March every… Read More
Pfizer and Astellas have announced positive top-line results from the Phase III EMBARK trial evaluating XTANDI (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR). Patients enrolled in the trial were randomised to one of three study arms: XTANDI plus leuprolide,… Read More
